By Toni Vranjes
Biotech company Versicor Inc. of Fremont and Italy's Biosearch Italia are breaking out the vino, celebrating their cross-Atlantic merger.
The combined company will develop antibiotic and anti-fungal treatments for a range of infections. The stock deal is valued at $261 million, based on Ver...
Biotech company Versicor Inc. of Fremont and Italy's Biosearch Italia are breaking out the vino, celebrating their cross-Atlantic merger.
The combined company will develop antibiotic and anti-fungal treatments for a range of infections. The stock deal is valued at $261 million, based on Ver...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In